Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?

Michael S. Kinch; Caitlin Horn; Zachary Kraft; Tyler Schwartz

doi:10.1021/acsptsci.0c00167

Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?

Michael S. Kinch
, Caitlin Horn
, Zachary Kraft
, Tyler Schwartz

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation.

Original language	English
Pages (from-to)	1427-1429
Number of pages	3
Journal	ACS Pharmacology and Translational Science
Volume	3
Issue number	6
DOIs	https://doi.org/10.1021/acsptsci.0c00167
State	Published - Dec 11 2020

Keywords

academic
biotechnology
founder
inventor
oncology
patent
pharmaceutical industry

Access to Document

10.1021/acsptsci.0c00167

Cite this

@article{590bac3dbbb746a0beb1401f79f21bc0,

title = "Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?",

abstract = "We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation.",

keywords = "academic, biotechnology, founder, inventor, oncology, patent, pharmaceutical industry",

author = "Kinch, \{Michael S.\} and Caitlin Horn and Zachary Kraft and Tyler Schwartz",

note = "Funding Information: This work was supported by the Washington University School of Medicine and a generous grant from the Mark Cuban Foundation. Publisher Copyright: {\textcopyright} ",

year = "2020",

month = dec,

day = "11",

doi = "10.1021/acsptsci.0c00167",

language = "English",

volume = "3",

pages = "1427--1429",

journal = "ACS Pharmacology and Translational Science",

issn = "2575-9108",

number = "6",

}

TY - JOUR

T1 - Rising Academic Contributions to Drug Development

T2 - Evidence of Vigor or Trauma?

AU - Kinch, Michael S.

AU - Horn, Caitlin

AU - Kraft, Zachary

AU - Schwartz, Tyler

N1 - Funding Information: This work was supported by the Washington University School of Medicine and a generous grant from the Mark Cuban Foundation. Publisher Copyright: ©

PY - 2020/12/11

Y1 - 2020/12/11

N2 - We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation.

AB - We analyzed therapeutic areas most commonly targeted by academia since 2001, finding a domination of certain oncology and infectious diseases. These findings raise important questions about whether this trend reflects an expanded opportunity arising from academic research or a troubling sign of an industry struggling with the challenges of innovation.

KW - academic

KW - biotechnology

KW - founder

KW - inventor

KW - oncology

KW - patent

KW - pharmaceutical industry

UR - https://www.scopus.com/pages/publications/85096013094

U2 - 10.1021/acsptsci.0c00167

DO - 10.1021/acsptsci.0c00167

M3 - Review article

C2 - 34723140

AN - SCOPUS:85096013094

SN - 2575-9108

VL - 3

SP - 1427

EP - 1429

JO - ACS Pharmacology and Translational Science

JF - ACS Pharmacology and Translational Science

IS - 6

ER -

Rising Academic Contributions to Drug Development: Evidence of Vigor or Trauma?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this